Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema.

ABSTRACT:

Background

Chronic Hand Eczema (CHE) is a prevalent inflammatory skin condition characterized by pain, pruritus and significant impact on patients' quality of life. Delgocitinib cream, a pan-Janus kinase inhibitor, has shown potential in targeting the key mediators of CHE. To develop a detailed trial drug safety profile, it is vital to assess systemic exposure and bioavailability following repeated drug applications.

Objectives

This analysis aimed to evaluate the systemic exposure and bioavailability of delgocitinib cream 20 mg/g in adults with moderate to severe CHE and compare these parameters with those from oral delgocitinib administration in healthy adults.

Methods

An open-label, single-arm, Phase 1 trial (NCT05486117) was conducted involving 16 adults with moder

SUBMITTER: Thaci D 

PROVIDER: S-EPMC12376242 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature